Literature DB >> 29532531

Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues.

I Arias de la Rosa1, A Escudero-Contreras1, S Rodríguez-Cuenca2, M Ruiz-Ponce1, Y Jiménez-Gómez1, P Ruiz-Limón1, C Pérez-Sánchez1, M C Ábalos-Aguilera1, I Cecchi1,3, R Ortega1, J Calvo1, R Guzmán-Ruiz4,5, M M Malagón4,5, E Collantes-Estevez1, A Vidal-Puig2, Ch López-Pedrera1, N Barbarroja1,5.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) patients are at increased risk of insulin resistance (IR); however, the specific mechanisms mediating this association are currently unknown.
OBJECTIVE: To investigate whether the inflammatory activity associated with RA accounts for the observed defective glucose metabolism and lipid metabolism in these patients.
METHODS: We followed two main strategies: (i) extensive metabolic profiling of a RA cohort of 100 patients and 50 healthy control subjects and (ii) mechanistic studies carried out in both a collagen-induced arthritis mouse model and 3T3-L1 adipocytes treated with conditioned serum from RA patients.
RESULTS: Following the exclusion of obese and diabetic subjects, data from RA patients demonstrated a strong link between the degree of systemic inflammation and the development of IR. These results were strengthened by the observation that induction of arthritis in mice resulted in a global inflammatory state characterized by defective carbohydrate and lipid metabolism in different tissues. Adipose tissue was most susceptible to the RA-induced metabolic alterations. These metabolic effects were confirmed in adipocytes treated with serum from RA patients.
CONCLUSIONS: Our results show that the metabolic disturbances associated with RA depend on the degree of inflammation and identify inflammation of adipose tissue as the initial target leading to IR and the associated molecular disorders of carbohydrate and lipid homeostasis. Thus, we anticipate that therapeutic strategies based on tighter control of inflammation and flares could provide promising approaches to normalize and/or prevent metabolic alterations associated with RA.
© 2018 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  adipose tissue; inflammation; insulin resistance; molecular pathways; rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 29532531     DOI: 10.1111/joim.12743

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  14 in total

Review 1.  Mechanistic and therapeutic links between rheumatoid arthritis and diabetes mellitus.

Authors:  Jing Li; Yazhuo Chen; Qingyun Liu; Zhufang Tian; Yan Zhang
Journal:  Clin Exp Med       Date:  2022-03-20       Impact factor: 3.984

2.  Trivalent chromium supplementation ameliorates adjuvant induced rheumatoid arthritis through up-regulation of FOXP3 and decrease in synovial Cathepsin G expression.

Authors:  Sally S Hassouna; Eman Sheta; Inass Zaki; Sahar A Harby; Eman A Allam
Journal:  Inflammopharmacology       Date:  2022-07-13       Impact factor: 5.093

3.  α-Mangostin Alleviated Inflammation in Rats With Adjuvant-Induced Arthritis by Disrupting Adipocytes-Mediated Metabolism-Immune Feedback.

Authors:  Ying-Hao Hu; Jun Han; Lin Wang; Chao Shi; Yan Li; Opeyemi Joshua Olatunji; Xiu Wang; Jian Zuo
Journal:  Front Pharmacol       Date:  2021-07-07       Impact factor: 5.810

4.  Skeletal muscle dysregulation in rheumatoid arthritis: Metabolic and molecular markers in a rodent model and patients.

Authors:  Nuria Casanova-Vallve; Dumitru Constantin-Teodosiu; Andrew Filer; Rowan S Hardy; Paul L Greenhaff; Victoria Chapman
Journal:  PLoS One       Date:  2020-07-07       Impact factor: 3.240

5.  Long Non-Coding RNAs Target Pathogenetically Relevant Genes and Pathways in Rheumatoid Arthritis.

Authors:  Marzia Dolcino; Elisa Tinazzi; Antonio Puccetti; Claudio Lunardi
Journal:  Cells       Date:  2019-08-02       Impact factor: 6.600

6.  Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis.

Authors:  Iván Arias de la Rosa; Pilar Font; Alejandro Escudero-Contreras; María Dolores López-Montilla; Carlos Pérez-Sánchez; María Carmen Ábalos-Aguilera; Lourdes Ladehesa-Pineda; Alejandro Ibáñez-Costa; Carmen Torres-Granados; Yolanda Jimenez-Gomez; Alejandra Patiño-Trives; María Luque-Tévar; María Carmen Castro-Villegas; Jerusalem Calvo-Gutiérrez; Rafaela Ortega-Castro; Chary López-Pedrera; Eduardo Collantes-Estévez; Nuria Barbarroja
Journal:  Ther Adv Chronic Dis       Date:  2020-10-21       Impact factor: 5.091

7.  Albumin/Globulin Ratio as Yin-Yang in Rheumatoid Arthritis and Its Correlation to Inflamm-Aging Cytokines.

Authors:  Kutty Selva Nandakumar; Dongzhou Liu; Yong Chen; Yanjuan Chen; Li Zhao; Hui He; Laiyou Wei; Wenjuan Lai; Jingxia Yuan; Xiaoping Hong; Lixiong Liu; Baojiang Wang
Journal:  J Inflamm Res       Date:  2021-10-27

Review 8.  Lipidomic Profiling in Synovial Tissue.

Authors:  Roxana Coras; Jessica D Murillo-Saich; Abha G Singh; Arthur Kavanaugh; Monica Guma
Journal:  Front Med (Lausanne)       Date:  2022-04-15

9.  Plasma Metabolome Normalization in Rheumatoid Arthritis Following Initiation of Methotrexate and the Identification of Metabolic Biomarkers of Efficacy.

Authors:  Matthew R Medcalf; Pooja Bhadbhade; Ted R Mikuls; James R O'Dell; Rebekah L Gundry; Ryan S Funk
Journal:  Metabolites       Date:  2021-11-30

10.  Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs.

Authors:  Iván Arias de la Rosa; Alejandro Escudero-Contreras; Miriam Ruiz-Ponce; Cristóbal Román-Rodríguez; Carlos Pérez-Sánchez; María Del Carmen Ábalos-Aguilera; Rafaela Ortega-Castro; Juan Alcaide; Mora Murri; Pilar Font; Jerusalem Calvo-Gutiérrez; Maria Luque-Tevar; Alejandra Maria Patiño-Trives; Rocío Guzmán-Ruiz; Maria Del Mar Malagón; Francisco José Tinahones; Eduardo Collantes-Estévez; Chary López-Pedrera; Nuria Barbarroja
Journal:  Front Immunol       Date:  2021-10-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.